Section
A large-scale trial in Brazilian ICUs found that daily chlorhexidine bathing did not lower overall nosocomial infection rates but significantly reduced multi-drug resistant pathogen isolation and the use of high-priority reserve antibiotics
This 24-month Belgian cohort study demonstrates that natural MPXV infection induces more durable and robust immunity than MVA-BN vaccination. While clinical symptoms mostly resolve within a year, persistent scarring remains common, and vacc
A randomized, double-blind trial in Kenya and Uganda reveals that a 500 IU fractional dose of yellow fever vaccine is not non-inferior to the standard dose in infants, suggesting that lower dose requirements in adults are not generalizable
The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for o
This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti
This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.
A large-scale cluster-randomized trial in Singapore demonstrates that releasing male Aedes aegypti mosquitoes infected with the wAlbB Wolbachia strain significantly suppresses wild-type populations and reduces the incidence of symptomatic d
Researchers have identified that a specific somatic hypermutation (K31E) in the IGLV3-21*02/03 allele triggers VITT by causing antibodies intended for adenoviral protein pVII to cross-react with Platelet Factor 4 (PF4), explaining the patho
The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping cl
A 2-year prospective cohort study reveals that physiological recovery, measured via smartwatches, significantly lags behind self-reported symptom resolution, particularly in moderate-to-severe COVID-19 cases, suggesting a need for revised p
The IMPROVE trial demonstrates that starting a one-month isoniazid-rifapentine (1HP) course during hospitalization for cryptococcal meningitis is as safe and effective as outpatient initiation, potentially increasing treatment completion ra
Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibito
A large-scale multicohort study reveals that adult obesity significantly increases the risk of hospitalization and death across nearly 1,000 infectious diseases, accounting for approximately one in ten infection-related deaths globally.
A phase 4 RCT in Brazil confirms that the recombinant zoster vaccine does not increase the risk of disease flares in patients with autoimmune rheumatic diseases compared to placebo, maintaining a favorable safety profile even under immunosu
This toxicological analysis of out-of-treatment people who inject drugs across five major US cities found that 93% tested positive for fentanyl, while xylazine prevalence surged in the Northeast, underscoring the critical need for real-time
A retrospective study of 148 state-level seasons reveals that RSV typically peaks three weeks before influenza, while COVID-19 lacks consistent seasonality, providing a critical framework for optimizing hospital resource allocation and vacc
A multicenter study reveals that 2024-2025 COVID-19 vaccines offer 40% protection against hospitalization and 79% against critical illness or death, maintaining efficacy against emerging JN.1 descendants like KP.3.1.1 and XEC.
A large-scale study reveals that RSV hospitalization significantly increases the risk of myocardial infarction, stroke, and heart failure exacerbations, with the highest risk occurring within the first week post-admission, emphasizing the c
The Phase IIa INSPIRE trial demonstrates that early administration of anakinra, guided by the presepsin biomarker, reduces the risk of organ dysfunction by 30% and significantly improves 90-day survival in hospitalized pneumonia patients, m
A comprehensive cost-of-illness analysis from the RAISE study reveals that Chagas disease imposes a massive economic burden on Latin American countries, driven by a shift toward chronic cardiac complications in aging populations, despite de
